Chuangyebang was informed that on April 19, Wanzhong Yixin, a startup company in the field of bio-microelectronics, announced the completion of 150 million RMB B+ round of financing. The lead investor in this round of financing is Qiming Venture Capital, Zhangjiagang Phoenix Technology and C&D Emerging Investment participated in the investment, and the old shareholders Matrix Partners and Desheng Fund continued to follow the investment.
This round of financing is mainly used for technical research and development, clinical certification, manufacturing, sales operations and site construction of its products.
Wanzhong Yixin focuses on the research and development, manufacturing and sales of semiconductor biochips, microfluidic laboratory chips and supporting instruments and molecular detection reagents. The mainstream products currently formed include small gene sequencers, portable nucleic acid detectors and supporting reagent cards.
After the global outbreak of the new crown virus in 2020, Wanzhong Yixin quickly developed a new crown integrated nucleic acid detection box suitable for home self-test. This product integrates the three steps of sample preparation, amplification and detection into a lighter-sized detection box, and has developed a constant temperature amplification reagent for the new coronavirus in conjunction with West China Hospital. The test box realizes the minimalist operation of “one touch, nucleic acid self-test”, and the results can be obtained within 30 minutes. It can be widely used in home testing, hospital outpatient clinics, primary medical institutions, and rapid nucleic acid screening in public places. .
In terms of team, Dr. Hu Wenchuan, the founder of Wanzhong Yixin, graduated from Peking University and obtained a Ph.D. in Molecular Electronics from the University of Notre Dame. Learning and R&D experience; currently the company has nearly 80 people, of which R&D personnel account for more than 70%, and have more than 110 intellectual property rights.
Mr. Hu Xubo, managing partner of Qiming Ventures, the leading investor in this round, said: “Gene sequencing technology is one of the foundations of precision medicine, and the existing gene sequencing technologies and products still have many problems in clinical application, convenience and cost. The demand to be met. The Wanzhong Yixin team founded and led by Professor Hu Wenchuan uses its own semiconductor and microfluidic technology to develop a new generation of gene sequencers and supporting equipment. We will actively participate in it and support the team to realize their dreams , create value for more patients.”
Dr. Yu Zhiyun, partner of Matrix Partners Ventures, the co-investor in this round, said: “In the past year, the company has made good progress in the sequencing equipment that abandons the optical path based on advanced semiconductor technology. At the same time, the company has successfully developed a household disposable nucleic acid for the detection of new crowns. The detection reagents are easy to use, affordable, and have the accuracy of traditional nucleic acid detection. I hope the company will continue to work hard and commercialization will be smooth.”
Mr. Wang Jun, the co-investor of this round and the managing partner of Desheng Capital, said: “We have invested in Wanzhong Yixin since 2017 and have invested in three consecutive rounds. The investment period of New Tongde Fund has ended, and now Desheng Capital is continuing to follow up. , which reflects our firm support and confidence in Professor Hu and the Wanzhong Yixin team. Such determination comes from the early stage of platform technology research and development, to the mass production of engineered products, and then to today’s market is about to bear fruit. Professor Hu As a semiconductor expert, leading the team in the field of molecular diagnostics and promoting the integration of medicine and industry from light to electricity, we have been carrying out subversive innovations. In the future, we will continue to accompany Professor Hu and his team to witness this kind of cross-border innovation to promote convenience and efficiency The rapid detection molecular diagnostic platform products benefit the general public and benefit mankind.”
attached
For more project information, please go to “Analysis of Rui Beast” .
media coverage
The investment community invests in China Net Venture State
This article is reproduced from: https://readhub.cn/topic/8fkJxB35mIw
This site is for inclusion only, and the copyright belongs to the original author.